Yuko Oya

senoor Assistant Professor

Fujita Health University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Yuko Oya is a senior Assistant Professor at Fujita Health University in Japan. His research focuses on liquid biopsy applications in oncology, particularly regarding EGFR mutations and resistance mechanisms in non-small cell lung cancer. He has contributed to studies examining the clinical impacts of pneumonitis during immunotherapy and the efficacy of immune checkpoint inhibitors in specific lung cancer subtypes.

Articles (13)

BACKGROUND Cisplatin-induced nephrotoxicity (CIN) is a major dose-limiting adverse event that can lead to both acute and chronic kidney injury. The formation of thiol-cisplatin conjugates within renal tubular cells has been implicated as a key mechanism underlying CIN. Flopropione is an inhibitor of cysteine conjugate β-lyase 1, an enzyme that catalyzes the formation of the thiol-cisplatin conjugate, which might prevent CIN. OBJECTIVE We designed a clinical trial to evaluate the safety of flopropione in patients receiving cisplatin-based chemotherapy and explore its efficacy in preventing CIN. METHODS This is a phase 1 and 2a, single-center, randomized, open-label trial conducted in patients undergoing cisplatin therapy. Participants are randomized in a 5:2 ratio per cohort to receive either flopropione or no treatment. On the day of cisplatin administration, the flopropione group receives oral flopropione twice daily (80 mg in cohort 1, 160 mg in cohort 2, and 240 mg in cohort 3). On the following day, all cohorts receive 3 doses of 80 mg of oral flopropione. A step-up dose escalation design is adopted, progressing from cohort 1 to 3 after confirming safety at each level. The primary end point is the safety of flopropione use in combination with cisplatin; the secondary end points include changes in the levels of urinary biomarkers of nephrotoxicity such as neutrophil gelatinase-associated lipocalin, liver-type fatty acid-binding protein, and kidney injury molecule-1. Blood and urine samples are collected within 48 hours before cisplatin administration and at 24 hours, 48 hours, and 1 week after its initiation for safety and efficacy assessments. RESULTS The first participant was registered in July 2024. As of January 2026, participant registration is ongoing. The final participant will complete the study by March 2026. Publication of results is expected by March 2027. CONCLUSIONS This study is expected to contribute to advances in preventive strategies for CIN by providing evidence that inhibition of cysteine conjugate β-lyase 1 by flopropione may attenuate CIN. CLINICALTRIAL Japan Registry of Clinical Trials jRCTs041220021; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041220021 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/87907

Year:

2025

Molecular profiling of tumors from patients plays a crucial role in precision oncology. While tumor tissue-based genomic testing remains the gold standard in clinical management of patients with non-small cell lung cancer, advances in genomic technologies, the analysis of various bodily fluids, mainly blood but also saliva, pleural/pericardial effusions, urine, and cerebrospinal fluid is now feasible and readily available. In this review, we will focus on the clinical application of circulating tumor DNA (ctDNA) in patients with non-small cell lung cancer in the setting of early-stage disease, locally advanced disease with attention to the potential of ctDNA in prognostication, risk stratification, minimal residual disease, and in advanced disease, its role in the detection of genomic markers and mechanisms of acquired resistance. The role of ctDNA and liquid biopsies in lung cancer screening will also be discussed.

Year:

2025

Purpose: E7389-LF is a liposomal formulation of eribulin that contributes to tumor vascular remodeling. The phase II part of this phase Ib/II study assessed the efficacy/safety of E7389-LF in combination with nivolumab in several disease cohorts; herein, we report results from the small cell lung cancer (SCLC) cohort. Experimental Design: Patients with unresectable/measurable SCLC and disease progression with first-line platinum-based chemotherapy with/without an immune checkpoint inhibitor (ICI) were enrolled to receive E7389-LF 2.1 mg/m 2 plus nivolumab 360 mg intravenously every 3 weeks. The primary objective of this part was to assess the objective response rate (ORR). Secondary objectives included assessments of safety and progression-free survival (PFS); exploratory assessments included overall survival (OS) and biomarkers. Results: Thirty-four patients were enrolled. By the data cut-off date (May 31, 2022), 29 (85.3%) had discontinued. Efficacy/biomarker analyses included 33 patients (1 had their diagnosis changed postenrollment); the ORR of E7389-LF plus nivolumab was 24.2% [95% confidence interval (CI): 11.1–42.3], the median PFS was 3.98 months (95% CI: 2.63–4.40), and, at a median follow-up of 10.6 months, the median OS was not reached (95% CI: not estimable). Notably, 27 of 33 patients (81.8%) had received an ICI as their prior first-line therapy. Treatment-related, treatment-emergent adverse events occurred in 97.1% (any grade) and 82.4% (grade ≥3) of enrolled patients; the most common event was neutropenia. Changes in vascular and immune-related plasma markers were observed. Conclusions: E7389-LF 2.1 mg/m 2 in combination with nivolumab 360 mg every 3 weeks showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared with either agent as monotherapy. Significance: This phase II part of a phase Ib/II study assessed liposomal eribulin (E7389-LF) plus nivolumab in 34 patients with pretreated SCLC; 8 of 33 evaluable patients (including 6/27 pretreated with ICIs) had objective responses. The combination was tolerable; increases in vasculature-related biomarkers tended to correlate with responses.

Year:

2024

Changes from baseline in select vasculature and IFN-related biomarkers weekly to C3D1 ( A ), per cycle to C8D1 ( B ), by tumor response (for vasculature-related biomarkers; C ), and by presence of prior ICI treatment (for IFN-related biomarkers; D ). Lines represent medians; error bars represent 95% CI. For box-and-whisker plots in C, the horizontal line represents the median, the box represents the interquartile range, the whiskers represent the largest or smallest values within 1.5 times the interquartile range (either above the 75th percentile or below the 25th percentile), and diamonds represent outliers. P values are: *, P P P A : n = 33 (C1D1, C1D8), n = 32 (C1D15), n = 30 (C2D1), n = 29 (C2D8), n = 28 (C2D15), n = 25 (C3D1). B : n = 33 (C1D1). n = 30 (C2D1), n = 25 (C3D1), n = 24 (C4D1), n = 19 (C5D1), n = 12 (C6D1), n = 8 (C7D1), n = 7 (C8D1). C : for CR/PR, n = 8 (C2D1, C3D1, C4D1); for non-CR/PR, n = 22 (C2D1), n = 17 (C3D1), n = 16 (C4D1). D : for prior ICI, n = 27 (C1D1, C1D8), n = 26 (C1D15), n = 25 (C2D1, C2D8, C2D15), n = 20 (C3D1); for no prior ICI, n = 6 (C1D1, C1D8, C1D15), n = 5 (C2D1), n = 4 (C2D8), n = 3 (C2D15), n = 5 (C3D1). C#D#, cycle #, day; CR, complete response; ICI, immune checkpoint inhibitor; IFNγ, interferon gamma; IP-10, IFN gamma-induced protein 10; MIG, monokine induced by gamma IFN; PECAM1, platelet endothelial cell adhesion molecule 1; PR, partial response; TEK, TEK receptor tyrosine kinase; TIE2, tyrosine kinase immunoglobulin and EGF homology domains 2.

Year:

2024

Swimmer plots of patients by course of treatment and dose reduction of E7389-LF ( A ) and lines of subsequent therapies received during survival follow-up ( B ). Patients could continue to receive study drugs beyond disease progression if they had investigator-assessed clinical benefit and were tolerating study drugs. This figure includes data from beyond disease progression. #L, line of treatment number; AE, adverse event; BSC, best supportive care; PD, progressive disease; PR, partial response.

Year:

2024

Swimmer plots of patients by course of treatment and dose reduction of E7389-LF ( A ) and lines of subsequent therapies received during survival follow-up ( B ). Patients could continue to receive study drugs beyond disease progression if they had investigator-assessed clinical benefit and were tolerating study drugs. This figure includes data from beyond disease progression. #L, line of treatment number; AE, adverse event; BSC, best supportive care; PD, progressive disease; PR, partial response.

Year:

2024

Percentage changes in sums of diameters of target lesions from baseline over time ( A ) a , and by PD-L1 CPS at nadir in all patients ( B ), patients with a biopsy ( C ), and patients with an archival tumor sample ( D ) a Patients could continue to receive study drugs beyond disease progression if they had investigator-assessed clinical benefit and were tolerating study drugs. A includes data from beyond disease progression. CPS, combined positive score; ICI, immune checkpoint inhibitor; N/A, not available; PD-L1, programmed cell death ligand 1.

Year:

2024

Changes from baseline in select vasculature and IFN-related biomarkers weekly to C3D1 ( A ), per cycle to C8D1 ( B ), by tumor response (for vasculature-related biomarkers; C ), and by presence of prior ICI treatment (for IFN-related biomarkers; D ). Lines represent medians; error bars represent 95% CI. For box-and-whisker plots in C, the horizontal line represents the median, the box represents the interquartile range, the whiskers represent the largest or smallest values within 1.5 times the interquartile range (either above the 75th percentile or below the 25th percentile), and diamonds represent outliers. P values are: *, P P P A : n = 33 (C1D1, C1D8), n = 32 (C1D15), n = 30 (C2D1), n = 29 (C2D8), n = 28 (C2D15), n = 25 (C3D1). B : n = 33 (C1D1). n = 30 (C2D1), n = 25 (C3D1), n = 24 (C4D1), n = 19 (C5D1), n = 12 (C6D1), n = 8 (C7D1), n = 7 (C8D1). C : for CR/PR, n = 8 (C2D1, C3D1, C4D1); for non-CR/PR, n = 22 (C2D1), n = 17 (C3D1), n = 16 (C4D1). D : for prior ICI, n = 27 (C1D1, C1D8), n = 26 (C1D15), n = 25 (C2D1, C2D8, C2D15), n = 20 (C3D1); for no prior ICI, n = 6 (C1D1, C1D8, C1D15), n = 5 (C2D1), n = 4 (C2D8), n = 3 (C2D15), n = 5 (C3D1). C#D#, cycle #, day; CR, complete response; ICI, immune checkpoint inhibitor; IFNγ, interferon gamma; IP-10, IFN gamma-induced protein 10; MIG, monokine induced by gamma IFN; PECAM1, platelet endothelial cell adhesion molecule 1; PR, partial response; TEK, TEK receptor tyrosine kinase; TIE2, tyrosine kinase immunoglobulin and EGF homology domains 2.

Year:

2024

Percentage changes in sums of diameters of target lesions from baseline over time ( A ) a , and by PD-L1 CPS at nadir in all patients ( B ), patients with a biopsy ( C ), and patients with an archival tumor sample ( D ) a Patients could continue to receive study drugs beyond disease progression if they had investigator-assessed clinical benefit and were tolerating study drugs. A includes data from beyond disease progression. CPS, combined positive score; ICI, immune checkpoint inhibitor; N/A, not available; PD-L1, programmed cell death ligand 1.

Year:

2024

Purpose: E7389-LF is a liposomal formulation of eribulin that contributes to tumor vascular remodeling. The phase II part of this phase Ib/II study assessed the efficacy/safety of E7389-LF in combination with nivolumab in several disease cohorts; herein, we report results from the small cell lung cancer (SCLC) cohort. Experimental Design: Patients with unresectable/measurable SCLC and disease progression with first-line platinum-based chemotherapy with/without an immune checkpoint inhibitor (ICI) were enrolled to receive E7389-LF 2.1 mg/m 2 plus nivolumab 360 mg intravenously every 3 weeks. The primary objective of this part was to assess the objective response rate (ORR). Secondary objectives included assessments of safety and progression-free survival (PFS); exploratory assessments included overall survival (OS) and biomarkers. Results: Thirty-four patients were enrolled. By the data cut-off date (May 31, 2022), 29 (85.3%) had discontinued. Efficacy/biomarker analyses included 33 patients (1 had their diagnosis changed postenrollment); the ORR of E7389-LF plus nivolumab was 24.2% [95% confidence interval (CI): 11.1–42.3], the median PFS was 3.98 months (95% CI: 2.63–4.40), and, at a median follow-up of 10.6 months, the median OS was not reached (95% CI: not estimable). Notably, 27 of 33 patients (81.8%) had received an ICI as their prior first-line therapy. Treatment-related, treatment-emergent adverse events occurred in 97.1% (any grade) and 82.4% (grade ≥3) of enrolled patients; the most common event was neutropenia. Changes in vascular and immune-related plasma markers were observed. Conclusions: E7389-LF 2.1 mg/m 2 in combination with nivolumab 360 mg every 3 weeks showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared with either agent as monotherapy. Significance: This phase II part of a phase Ib/II study assessed liposomal eribulin (E7389-LF) plus nivolumab in 34 patients with pretreated SCLC; 8 of 33 evaluable patients (including 6/27 pretreated with ICIs) had objective responses. The combination was tolerable; increases in vasculature-related biomarkers tended to correlate with responses.

Year:

2024

Year:

2021

Year:

2021

Year:

2020

Collaborators (11)

Tomohiro Mizuno

Associate professor

Fujita Health University

JAPAN
View details

Naotake Tsuboi

Associate Professor

Fujita Health University

JAPAN
View details

Hikaru Yabuuchi

Professor

Fujita Health University

JAPAN
View details

Ross Soo

National University Health System

SINGAPORE
View details

Kuniaki Saito

-

JAPAN
View details

Naozumi Hashimoto

Nagoya University Graduate School of Medicine

JAPAN
View details

Hideyuki Saya

Keio University

JAPAN
View details

Kenji Kawada

Professor

Fujita Health University

JAPAN
View details

Toshiyuki Kozuki

Kochi Medical School, Kochi University

JAPAN
View details

Koichi Azuma

Kurume University School of Medicine

JAPAN
View details

Daichi Fujimoto

Hyogo medical university

JAPAN
View details